Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables, and platform technology solutions to the worldwide life sciences
and other industries, today announced its receipt of a purchase order from a
new customer for six proprietary Ultra Shear Technology(TM) (“UST”)-based
nanoemulsification systems for processing CBD oil into stable, effectively
water-soluble, highly absorbable nanoemulsions of oil in water. According to
the update, such nanoemulsions are expected to exhibit bioavailability levels
that far exceed those of today’s macro or microemulsions of CBD oil. “In
addition to the new order for six BaroShear K45 systems, there are numerous
additional groups who have shown high levels of interest in acquiring the new
BaroShear K45 nanoemulsification system,” PBIO President and CEO Richard T.
Schumacher said in the news release. “Our team is diligently following up with
these interested parties; we believe that several of these groups will be
placing purchase orders with us in the very near future. These are very
exciting times for all PBIO stakeholders.”
To view the full press release, visit http://ibn.fm/LzTKT
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e., pressure
cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling
technology platform that uses alternating cycles of hydrostatic pressure
between ambient and ultra-high levels to safely and reproducibly control
bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s
primary focus is in the development of PCT-based products for biomarker and
target discovery, drug design and development, biotherapeutics characterization
and quality control, soil and plant biology, forensics and counter-bioterror
applications. Additionally, major new market opportunities have emerged in the
use of its pressure-based technologies in the following areas: (1) the use of
its recently acquired, patented technology from BaroFold Inc. (the “BaroFold”
technology) to allow entry into the biopharma contract services sector, and (2)
the use of its recently patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room-temperature, stable low-acid
liquid foods that cannot be effectively preserved using existing nonthermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
